NMN vs NR: Which NAD+ Precursor Raises NAD+ More

NMN and NR are not the same molecule doing the same job

Both get sold as “NAD+ boosters.” Both raise NAD+ in the blood when you take them. That’s where the similarity stops. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) enter the NAD+ salvage pathway at 2 different points, and the distance each has to travel changes what happens before it becomes usable NAD+.

NAD+, nicotinamide adenine dinucleotide, is the electron carrier that runs mitochondrial energy production, DNA repair through PARP enzymes, and the sirtuin family governing cellular stress response. It’s a cofactor every cell needs thousands of times a second, and the body’s ability to make it drops with age. Human muscle NAD+ has been measured at roughly half its young-adult level by the sixth decade of life.

The chain: where NMN and NR enter

NMN’s route is short. It converts straight to NAD+ via NMNAT (nicotinamide mononucleotide adenylyltransferase), in one step. There’s an open scientific argument over exactly how NMN gets into cells intact versus getting broken down to NR first and rebuilt, but functionally, NMN sits one enzymatic reaction from the finish line.

NR’s route has an extra station. Nicotinamide riboside first gets phosphorylated into NMN by nicotinamide riboside kinase (NRK1 or NRK2) before reaching that same NMNAT step. NRK1 is the workhorse copy, expressed unevenly across tissue types, part of why NR’s effects show up more clearly in some organs (skeletal muscle, cardiovascular tissue) than others in the human trials so far.

A third route is the one your body runs by default: the salvage pathway recycles nicotinamide, NAD+’s own breakdown product, back into NMN using an enzyme called NAMPT. NAMPT is the rate-limiting enzyme of the whole system, and its activity falls with age. That’s the actual bottleneck neither NMN nor NR fixes directly; both precursors bypass NAMPT and feed the chain further downstream.

Law 2: Chain Optimization, and why the sink matters as much as the source

This is the second of my Laws of Biochemistry Physics: the body runs on linked chains, not single switches. You can’t fix one link and assume the whole system speeds up, because the slowest station on the line sets total output. An assembly line with 1 fast machine and 4 slow ones ships at the speed of the slow ones.

NAD+ synthesis is a textbook case. NMN skips the NRK bottleneck. NR skips the NAMPT bottleneck. Both converge on NMNAT, which has enough capacity in most healthy adults that it isn’t the limiting station. So far this looks like a straightforward problem: pick the shorter chain, get more NAD+.

Except the chain doesn’t end at NAD+. It ends wherever NAD+ gets consumed, and the dominant consumer in aging tissue is CD38, a membrane-bound enzyme that hydrolyzes NAD+ (and NMN directly) back down. CD38 expression and activity rise with age, driven largely by immune cell infiltration as the body accumulates senescent cells. Mouse data found CD38 knockout animals held close to youthful NAD+ at 32 months old while wild-type mice had dropped to about half. That’s a sink problem: no amount of upstream precursor floods a sink that’s draining faster than you can fill it.

The practical read: precursor choice determines how efficiently you refill the chain. CD38 activity, which tracks more with inflammation and senescent cell burden than with age in years, determines how long what you refill actually stays.

What the human trials found

On NMN: a 12-week trial in healthy older Japanese men at 250 mg a day raised blood NAD+ and its metabolites, well tolerated with no meaningful change in heart rate, blood pressure, or standard labs. A separate 10-week trial in postmenopausal women with prediabetes, also at 250 mg a day, increased muscle insulin sensitivity and signaling without changing weight or body composition. A dose-ranging trial across 300, 600, and 900 mg a day raised blood NAD+ at every dose by day 30, and improved 6-minute walking distance at all 3 doses by day 60.

On NR: the first human pharmacokinetics trial found single doses of 100, 300, and 1,000 mg produced a dose-dependent rise in blood NAD+ metabolites, no serious side effects. A 6-week crossover in adults aged 55 to 79 at 1,000 mg a day (split into 2 500 mg doses) raised NAD+ about 60 percent and cut systolic blood pressure roughly 10 points in the subset who started elevated. A 12-week trial in obese, insulin-resistant men at 2,000 mg a day raised NR metabolites and plasma triglycerides but didn’t move insulin sensitivity on a hyperinsulinemic clamp, the gold-standard test. A 21-day crossover in aged men at 1,000 mg a day raised the muscle NAD+ metabolome and triggered anti-inflammatory gene changes, no detectable shift in mitochondrial bioenergetics.

Read across all of it: NAD+ rises on both compounds, reliably, at every dose tested. What moves downstream (insulin sensitivity, blood pressure, walking speed) is inconsistent and tissue-dependent. Neither has a large trial showing it extends lifespan or reverses a disease state in humans.

The FDA status, because it changed twice

In November 2022, the FDA told ingredient suppliers NMN was excluded from the legal definition of a dietary supplement, because it had been investigated as a drug first. That triggered a citizen petition fight from the Natural Products Association and the Alliance for Natural Health USA. The FDA reversed course in September 2025, concluding NMN was marketed as a supplement before any drug investigation began, then followed with letters in December 2025 reinstating its New Dietary Ingredient status. NMN is lawful to sell again as of this writing, still classified as an NDI with premarket notification requirements. NR was never caught in that fight.

The Natural Plus Protocol take

I’ve run both compounds over the years, cycling between them rather than staying on one indefinitely. NMN and NR aren’t competing for the same job, so “which one is better” is the wrong question before answering what you’re optimizing for.

If the goal is metabolic, insulin sensitivity, muscle function, the NMN data has more depth right now. If the goal is cardiovascular, blood pressure, arterial stiffness, the NR data has more depth. The trials ran 250 to 900 mg a day for NMN and 100 to 1,000 mg a day for NR, most of the meaningful ones split into 2 doses. I take mine in the morning, with food, because NAD+ demand tracks with mitochondrial activity and I want the precursor available when my day’s output is highest.

Cycling matters more here than most compounds I write about, because the actual lever, CD38 activity, isn’t something either precursor touches. Running one continuously while ignoring what keeps CD38 elevated optimizes the wrong link in the chain. Bloodwork worth tracking before calling a precursor “working”: fasting insulin, hs-CRP as a rough inflammation proxy, resting blood pressure if NR is the one running. NAD+ itself isn’t practically testable through a standard lab; the trials used specialized metabolomics panels most people can’t order.

Stacking: what shares a different pathway

Law 5, independent receptor stacking, says compounds hitting separate pathways add together instead of competing for the same output. An NAD+ precursor doesn’t compete with rapamycin’s mTOR inhibition or metformin’s AMPK activation. 3 different levers on 3 different systems, each touching aging from a different angle.

Approach	Pathway	Why it’s independent, not redundant
Rapamycin	mTOR inhibition	Slows growth signaling, turns up autophagy, doesn’t touch the NAD+ pool. See my 18-month rapamycin bloodwork writeup.
Metformin	AMPK activation	Energy sensing upstream of where NAD+ gets spent, covered in my metformin for anti-aging piece.
Resistance training	Mechanical + metabolic stress	Raises NAMPT activity on its own, doing part of what the precursor shortcuts. My heavy lifting breakdown covers it.

I don’t have a product on the Enhanced Labs shelf built around NMN or NR, so I’m not forcing a link where there isn’t a real one. If that changes, I’ll update this page.

Who this is for

Adults past 40 who’ve already handled the basics (sleep, resistance training, protein intake) and are looking at the next layer down. People already running rapamycin or metformin who want a third lever that doesn’t overlap mechanically. Anyone with elevated blood pressure or borderline insulin resistance wanting to see which precursor’s trial data lines up closer to their own number. Not for someone expecting either compound to substitute for the training and diet work that actually moves the CD38 side of the chain; nothing in the trial data supports that.

Timeframe	What the trials showed
Week 1-2	Blood NAD+ metabolites rise measurably within days on both compounds. No subjective difference reported at this stage.
Week 4	NMN’s dose-ranging trial had already detected a NAD+ rise across all 3 doses. Functional changes (walking speed, blood pressure) hadn’t yet separated from placebo in most trials.
Week 8	NR’s blood pressure trial and NMN’s walking-speed and insulin-sensitivity trials all reported their clearest separation from placebo here.
Week 12	Longest window most trials have run. Sleep and physical performance measures held in the NMN trials tracking them this far; nothing has followed subjects past 12 weeks to see if effects plateau or fade.

Interesting perspectives

The NMN transport question is still an open fight in the literature. One camp proposes a direct transporter, SLC12A8. Another argues NMN gets dephosphorylated to NR outside the cell and rebuilt inside, meaning the “shorter chain” advantage might not hold at the cellular level the way it holds on paper. I’d treat NMN’s mechanistic edge as directionally right, not settled.

The muscle insulin sensitivity result is real and underrated, but it’s one trial, in one population, postmenopausal women with prediabetes, unreplicated in men or healthy adults. Extrapolating it to “NMN fixes insulin resistance” is the overreach that gives this category a bad name.

My contrarian take: the “NMN vs NR” debate spends its energy on the supply side of the chain while ignoring the demand side. CD38 tracks with senescent cell burden and chronic low-grade inflammation more than with calendar age. People the same age can carry very different CD38 activity depending on how much unresolved inflammation they’re running. The honest answer to “which precursor should I run” is often “neither, until you’ve addressed why your sink is running hot,” and almost nobody selling either compound leads with that.

Cross-domain connection worth watching: researchers working on senolytics (compounds that clear senescent cells) are now pairing them with NAD+ precursors, on the theory that clearing the cells driving the CD38 signal while refilling the pool beats doing either alone. That combination hasn’t reached a human trial yet. It’s where I’d watch next, not what to buy.

For the anti-aging supplements I run, start at the supplements hub, my take on anti-aging pills, and where NAD+ shows up outside the longevity conversation, in long COVID recovery. For the bigger question behind all of it, read what drives healthy aging before you go broke on precursors.

FAQ

What is NMN?
A molecule one enzymatic step upstream of NAD+. The body converts it directly to NAD+ via NMNAT. Human trials at 250 to 900 mg a day have consistently raised blood NAD+.

Is NMN or NR better at raising NAD+?
Both raise blood NAD+ reliably at every dose tested. NMN’s chain to NAD+ is shorter on paper; NR has more trial data on downstream effects like blood pressure and arterial stiffness. No head-to-head human trial exists, so “better” depends on the outcome targeted.

Are NMN and NR safe, and what are the side effects?
Across the trials cited here, both were well tolerated with no serious adverse events. One NR trial found higher plasma triglycerides at 2,000 mg a day, worth tracking on bloodwork at that dose.

Can I stack NMN or NR with rapamycin or metformin?
Yes. Rapamycin works through mTOR inhibition, metformin through AMPK activation, and NAD+ precursors run a separate salvage pathway. Independent receptor stacking, not redundant stacking.

Who should consider an NAD+ precursor for anti-aging?
Adults past 40 who’ve already built the training, sleep, and diet foundation and are adding a targeted layer. Not a substitute for the habits that keep CD38 and inflammation in check, and the human data doesn’t support treating it as one.